Terms: = Thyroid cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
284 results:
1. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
[TBL] [Abstract] [Full Text] [Related]
2. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
3. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and Characterization of Amitrole-Induced Mouse thyroid Adenomatous Nodule-Derived Cell Lines.
Shirai YT; Hoshi N; Ward JM; Liu H; Cachau RE; Lee MP; Kimura S
Thyroid; 2024 Apr; 34(4):496-509. PubMed ID: 38149583
[No Abstract] [Full Text] [Related]
5. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic thyroid cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract] [Full Text] [Related]
6. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants.
Ahmed S; Wedekind MF; Del Rivero J; Raygada M; Lockridge R; Glod JW; Flowers C; Thomas BJ; Bernstein DB; Kapustina OB; Jain A; Miettinen M; Raffeld M; Xi L; Tyagi M; Kim J; Aldape K; Malayeri AA; Kaplan RN; Allen T; Vivelo CA; Sandler AB; Widemann BC; Reilly KM;
Cancer Res Commun; 2023 Dec; 3(12):2468-2482. PubMed ID: 37966258
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of the thyroid cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
[No Abstract] [Full Text] [Related]
9. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract] [Full Text] [Related]
10. Systematic pharmacology-based strategy to explore the mechanism of Semen Strychni for treatment of papillary thyroid carcinoma.
Mao J; Tang L; Fang L; Tian C; Zhu Z; Li Y
Sci Rep; 2023 Oct; 13(1):18492. PubMed ID: 37898675
[TBL] [Abstract] [Full Text] [Related]
11. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract] [Full Text] [Related]
12. Nanotechnological Advancements for the Theranostic Intervention in Anaplastic thyroid cancer: Current Perspectives and Future Direction.
Uppalapati SS; Guha L; Kumar H; Mandoli A
Curr Cancer Drug Targets; 2024; 24(3):245-270. PubMed ID: 37424349
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
14. Expression and regulatory network of E3 ubiquitin ligase NEDD4 family in cancers.
Cao L; Li H; Liu X; Wang Y; Zheng B; Xing C; Zhang N; Liu J
BMC Cancer; 2023 Jun; 23(1):526. PubMed ID: 37291499
[TBL] [Abstract] [Full Text] [Related]
15. Bioinformatics analysis of the prognostic and clinical value of senescence-related gene signature in papillary thyroid cancer.
Wen T; Guo S
Medicine (Baltimore); 2023 Jun; 102(22):e33934. PubMed ID: 37266618
[TBL] [Abstract] [Full Text] [Related]
16. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
[No Abstract] [Full Text] [Related]
17. Investigation of the mechanism of Prunella vulgaris in treatment of papillary thyroid carcinoma based on network pharmacology integrated molecular docking and experimental verification.
Zhu X; Li Y; Wang X; Huang Y; Mao J
Medicine (Baltimore); 2023 Apr; 102(17):e33360. PubMed ID: 37115092
[TBL] [Abstract] [Full Text] [Related]
18. Type 2 deiodinase is expressed in anaplastic thyroid carcinoma and its inhibition causes cell senescence.
Angela De Stefano M; Porcelli T; Ambrosio R; Luongo C; Raia M; Schlumberger M; Salvatore D
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36877008
[TBL] [Abstract] [Full Text] [Related]
19. Validation of EZH2 Inhibitor Efficiency in Anaplastic thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
20. Spontaneous Murine Model of Anaplastic thyroid cancer.
Yan H; Ma Y; Zhou X; He Y; Liu Y; Caulin C; Wang L; Xu H; Luo H
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36804915
[TBL] [Abstract] [Full Text] [Related]
[Next]
